Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Pilot Study of Quetiapine Treatment of Aggression Due to Traumatic Brain Injury

A Pilot Study of Quetiapine Treatment of Aggression Due to Traumatic Brain Injury ABSTRACT In a 6-week open-label, flexible dose pilot study of quetiapine for treatment of aggression secondary to traumatic brain injury (TBI), seven subjects who were at least 3-months post-injury were enrolled. The Overt Aggression Scale – Modified (OAS-M) and Clinical Global Impression (CGI) were primary outcome measures. Administration of quetiapine at doses of 25 to 300mg daily was efficacious and well-tolerated in reducing irritability and aggression resulting from TBI, with an associated improvement in cognitive functioning. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Neuropsychiatry & Clinical Neurosciences American Psychiatric Publishing, Inc (Journal)

A Pilot Study of Quetiapine Treatment of Aggression Due to Traumatic Brain Injury

Download PDF

A Pilot Study of Quetiapine Treatment of Aggression Due to Traumatic Brain Injury

Kim, Edward; Bijlani, Mona
Journal of Neuropsychiatry & Clinical Neurosciences , Volume 18 (4): 547 – Nov 1, 2006

Abstract

ABSTRACT In a 6-week open-label, flexible dose pilot study of quetiapine for treatment of aggression secondary to traumatic brain injury (TBI), seven subjects who were at least 3-months post-injury were enrolled. The Overt Aggression Scale – Modified (OAS-M) and Clinical Global Impression (CGI) were primary outcome measures. Administration of quetiapine at doses of 25 to 300mg daily was efficacious and well-tolerated in reducing irritability and aggression resulting from TBI, with an associated improvement in cognitive functioning.

Loading next page...
 
/lp/american-psychiatric-publishing-inc-journal/a-pilot-study-of-quetiapine-treatment-of-aggression-due-to-traumatic-yAbz2EP3xe

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Psychiatric Publishing, Inc (Journal)
Copyright
Copyright © 2006 American Neuropsychiatric Association. All rights reserved.
ISSN
0895-0172
DOI
10.1176/appi.neuropsych.18.4.547
Publisher site
See Article on Publisher Site

Abstract

ABSTRACT In a 6-week open-label, flexible dose pilot study of quetiapine for treatment of aggression secondary to traumatic brain injury (TBI), seven subjects who were at least 3-months post-injury were enrolled. The Overt Aggression Scale – Modified (OAS-M) and Clinical Global Impression (CGI) were primary outcome measures. Administration of quetiapine at doses of 25 to 300mg daily was efficacious and well-tolerated in reducing irritability and aggression resulting from TBI, with an associated improvement in cognitive functioning.

Journal

Journal of Neuropsychiatry & Clinical Neurosciences – American Psychiatric Publishing, Inc (Journal)

Published: Nov 1, 2006

There are no references for this article.